Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

2.50
Hdl Handle:
http://hdl.handle.net/10541/75868
Title:
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Authors:
Robertson, John F R; Howell, Anthony ( 0000-0002-3879-5991 ) ; Gorbunova, V A; Watanabe, Toru; Pienkowski, Tadeusz; Lichinitser, M R
Abstract:
There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician's discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy.
Affiliation:
Unit of Surgery, City Hospital, NG5 1PB, Nottingham, UK. John.Robertson@nottingham.ac.uk
Citation:
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. 2005, 92 (2):169-74 Breast Cancer Res. Treat.
Journal:
Breast Cancer Research and Treatment
Issue Date:
Jul-2005
URI:
http://hdl.handle.net/10541/75868
DOI:
10.1007/s10549-004-4776-0
PubMed ID:
15986127
Type:
Article
Language:
en
ISSN:
0167-6806
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRobertson, John F R-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorGorbunova, V A-
dc.contributor.authorWatanabe, Toru-
dc.contributor.authorPienkowski, Tadeusz-
dc.contributor.authorLichinitser, M R-
dc.date.accessioned2009-07-29T14:22:23Z-
dc.date.available2009-07-29T14:22:23Z-
dc.date.issued2005-07-
dc.identifier.citationSensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. 2005, 92 (2):169-74 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806-
dc.identifier.pmid15986127-
dc.identifier.doi10.1007/s10549-004-4776-0-
dc.identifier.urihttp://hdl.handle.net/10541/75868-
dc.description.abstractThere is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician's discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Metastasisen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEstradiol-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMedroxyprogesterone 17-Acetate-
dc.subject.meshMegestrol Acetate-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshPostmenopause-
dc.subject.meshRetrospective Studies-
dc.subject.meshSalvage Therapy-
dc.subject.meshTamoxifen-
dc.subject.meshTreatment Outcome-
dc.titleSensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.en
dc.typeArticleen
dc.contributor.departmentUnit of Surgery, City Hospital, NG5 1PB, Nottingham, UK. John.Robertson@nottingham.ac.uken
dc.identifier.journalBreast Cancer Research and Treatmenten
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.